The presence of activation peptides (AP) of the vitamin K-dependent proteins in the phlebotomy blood of human subjects suggests that active serine proteases may circulate in blood as well. The goal of the current study was to evaluate the influence of trace amounts of key coagulation proteases on tissue factor independent thrombin generation using three models of coagulation.
SUMMARY
The presence of activation peptides (AP) of the vitamin K-dependent proteins in the phlebotomy blood of human subjects suggests that active serine proteases may circulate in blood as well. The goal of the current study was to evaluate the influence of trace amounts of key coagulation proteases on tissue factor independent thrombin generation using three models of coagulation.
With procoagulants and select coagulation inhibitors at mean physiological concentrations, concentrations of factor IXa, factor Xa and thrombin were set either equal to those of their AP or to values which would result based upon the rates of AP/enzyme generation and steady state enzyme inhibition. In the latter case, numerical simulation predicts that sufficient thrombin to produce a solid clot would be generated in 2 min. Empirical data from the synthetic plasma suggest clotting times of 3-5 min, which are similar to that observed in contact pathway inhibited whole blood (4.3 min) initiated with same concentrations of factors IXa and Xa and thrombin.
Numerical simulations performed with the concentrations of two of the enzymes held constant and one varied suggest that the presence of any pair of enzymes is sufficient to yield rapid clot formation. Modeling of states (numerical simulation and whole blood) where only one circulating protease is present at steady state concentration shows significant thrombin generation only for factor IXa. The addition of factor Xa and thrombin has little effect (if any) on thrombin generation induced by factor IXa alone. These data indicate that: 1) concentrations of active coagulation enzymes circulating in vivo are significantly lower than can be predicted from the concentrations of their AP; 2) expected trace amounts of factor IXa can trigger thrombin generation in the absence of tissue factor.
INTRODUCTION
Five vitamin K-dependent proteins serve as precursors for serine proteases, which are essential for normal hemostasis (factors VII, IX, and X, prothrombin and protein C) (1) . The zymogens are converted to fully functional enzymes by the proteolytic removal of corresponding activation peptides. The only exception is factor VII, which is converted to an active enzyme by a single cleavage not followed by the release of an activation peptide (2) . For the release of activation peptides from factor X, protein C and prothrombin, single cleavages are required, whereas the activation peptide of factor IX is generated by two proteolytic cleavages (3) . The length of activation peptides varies from 12 amino acids for protein C to 271 amino acids for prothrombin (Fragment 1.2). There are no structural domains observed for activation peptides of factor IX, factor X and protein C. However, fragment 1.2 of prothrombin contains a Gla-domain and two kringle domains. The former one is rich in -carboxyglutamic acid residues and facilitates a calcium-dependent binding of prothrombin to the membranes containing acidic phospholipids (1) . The kringle domain 1 contains two of three prothrombin glycosylation sites (4) .
The detection of activation peptides of the vitamin K-dependent proteins in plasma of human subjects suggests that active serine proteases may circulate in blood either as a result of continuous in situ production ("idling motor") or as a consequence of production during localized coagulation ("historical record"). The relationship between the concentrations of enzymes and their corresponding activation peptides is not clear in part because the source(s) of these peptides is not identified. A possible trigger for the generation of these peptides and corresponding enzymes can be active tissue factor hypothetically circulating in blood (5).
Alternatively, they can be generated due to the initiation of the coagulation cascade during phlebotomy and processing of blood. The key problem for the evaluation of active enzymes is that direct assays of these serine proteases are difficult (if possible at all) due to their rapid neutralization by the natural inhibitors present in blood.
To circumvent this obstacle, assays for the activation peptides released during the generation of serine proteases involved in blood coagulation as well as for the reaction and inhibition products of these enzymes have been developed (6) (7) (8) (9) (10) (11) . Products, including activation peptides of prothrombin, factor X and factor IX, related to the processes leading to thrombin generation and clot formation have been used as markers for the assessment of the coagulation state of human beings. Elevated levels of activation peptides are observed in patients suffering from disseminated intravascular coagulation (11, 12) , deep vein thrombosis (13, 14) , coronary heart disease (15, 16), unstable angina, myocardial infarction (17, 18) , and other coagulation-related disorders (19) . The concentrations of activation peptides are also affected by deficiencies or mutations in procoagulants and coagulation inhibitors (10, (20) (21) (22) (23) (24) , by smoking (25) and by age (26) .
Although there is a strong correlation between the prothrombotic state of individuals and estimated levels of activation peptides, the question whether these levels reflect concentrations of active enzymes circulating in vivo remains open. The validity of this question can be illustrated by the observation that estimated activation peptide levels are dependent upon the conditions of sample collection (27, 28) .
In the current study we evaluated the capability of thrombin, factor Xa and factor IXa to trigger thrombin generation and clot formation, when these enzymes are present at concentrations relevant to those reported for their activation peptides in healthy individuals. Three in vitro models of coagulation developed in our laboratory were used to achieve this goal (29) (30) (31) (32) (33) (34) .
EXPERIMENTAL PROCEDURES
Materials-Human coagulation factors VII, X, IX, and prothrombin, were isolated from fresh frozen plasma using the general methods of Bajaj et al. (35) , and were purged of trace contaminants and traces of active enzymes as described (36). Human factor V and AT-III were isolated from freshly frozen plasma (37, 38) . Recombinant factor VIII and recombinant tissue factor (TF) (residues 1-242) were provided as gifts from Drs. Shu Len Liu and Roger Lundblad (Hyland division, Baxter Healthcare Corp, Duarte, CA). Recombinant human factor VIIa was provided as a gift from Dr. Ula Hedner (Novo Nordisk, Denmark). Recombinant full-length TFPI produced in Escherichia coli was provided as a gift by Dr. K. Johnson (Chiron Corp, Emeryville, CA). Factor IXa, factor Xa and -thrombin were provided as a gift by Dr. R. Jenny (Haematologic Technologies, Essex Junction, VT). Corn trypsin inhibitor (CTI) was isolated from popcorn as described elsewhere (34) . Washed platelets were prepared by the procedure of Mustard et al. (39) . Preparation of the TF/lipid reagent was done as described elsewhere (34).
1,2-Dioleolyl-sn-Glycero-3-Phospho-L-Serine (PS) and 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (PC) were purchased from Avanti Polar Lipids, Inc (Alabaster, AL), and EDTA (Ca ++ quencher) was purchased from Sigma (St Louis, MO). Phospholipid vesicles (PCPS) composed of 25% PS and 75% PC were prepared as described (40) . Spectrozyme TH was purchased from American Diagnostica, Inc (Greenwich, CT). D-Phe-Pro-ArgCH 2 Cl (FPRck) and the fluorogenic substrate 6-(D-Val-Pro-Arg)amino-1-naphthalene(n-butyl)sulfonamide (VPRnbs) (41) were synthesized in house. Recombinant hirudin was a gift from Genentech. ELISA thrombin-AT-III (TAT) kit (Enzygnost TAT) was purchased from Behring (Marburg, Germany).
Numerical simulation-The present effort is based upon prior publications by Jones et al. (29) and Hockin et al. (30) . An additional step of factor X activation by factor IXa was incorporated using kinetic constants published by Walsh and coworkers (42) Plasma preparation for the fluorogenic assay. Blood (10 ml) from a healthy volunteer was drawn into a syringe loaded with 10 ml HBS containing 50 mM EDTA, pH 7.4. The platelet poor plasma (PPP) was made by centrifugation at 3,000 rpm for 20 min followed by the centrifugation at 11,000 rpm (20,000 x g) for 10 min. When kept on ice, plasma did not clot for at least 10 h.
One fraction of the PPP was used for the fluorogenic assay immediately and another one was spiked with 1 pM -thrombin and kept for 1 h before the assay. Estimation of the in vivo concentrations of free enzymes-The concentration of a given free enzyme in a dynamic system containing stoichiometric inhibitors is determined by the balance between the rate of enzyme generation and the rate(s) of inhibition. Assuming that the concentrations of inhibitors are relatively constant in blood under normal flow, the concentration of free enzyme can be described by the following equation: v= k 1 (30) , and E f is free enzyme.
The rate of generation of each enzyme was assumed to be equal to the rate of removal of its activation peptide from blood (19) . The latter was assumed to be a first order process and the rate constant (k AP ) could be calculated using the reported half-life for each activation peptide (AP) (see Table 1 ). Ongoing rates of activation peptide removal and equal rates of enzyme formation are then defined as the product k AP [AP] using reported steady state concentrations of activation peptides (13) (14) (15) (16) (17) (20) (21) (22) (23) (24) (25) (26) . These rate estimates are used to calculate [E f ] for each enzyme using the above equation and reported concentrations of inhibitors and their second order rate constants of inhibition for the particular enzyme.
Operational definitions. The initiation phase of thrombin generation was defined as a time interval from the start of the reaction (represented by 0 on the x-axis in figures) to the point of intersection of the x-axis and a tangent to the maximum slope of thrombin generation. It is characterized by relatively slow prothrombin activation and the proteolytic processing steps required for the assembly of the vitamin K-dependent protein activating complexes. The propagation phase of thrombin generation is defined as a time interval from the end of the initiation phase to the maximum thrombin concentration. It is characterized by robust prothrombin activation principally by factor Xa·factorVa·membrane, i.e. the prothrombinase complex with factor Xa provided predominantly by the factor IXa-factor VIIIa complex, the intrinsic factor Xase. The enzyme concentrations selected for the initial studies of thrombin generation were either equal to those of activation peptides or decreased in sequential studies by orders of magnitude.
RESULTS

Numerical simulations predicting the influence of simultaneous variations of thrombin, factor
However, the free enzymes continuously generated in vivo, would be inhibited by the inhibitors present in blood, primarily by AT-III and TFPI. Our calculations based upon activation peptide/enzyme generation and enzyme inhibition rates suggest that the steady state concentrations of coagulation serine proteases for the "idling motor" assumption should be 5.3 pM for thrombin, 5.5 pM for factor Xa and 97 pM for factor IXa (see Experimental Procedures and Table 1 ). At these enzyme concentrations, the initiation phase duration would be 160 s (Figure 1, ) . Thus blood containing these enzyme concentrations would clot in less than 3 min.
The maximum concentration of active thrombin achieved is 780 nM and the maximum rate of thrombin generation is 17 nM/s.
Variations of a single enzyme concentration in numerical simulations in the presence of two
other enzymes-In an attempt to determine which one enzyme of the mixture of three potential resident enzymes would have the most significant impact on thrombin generation, the concentration of the selected enzyme was varied, while concentrations of the other two were kept at the levels of their activation peptides. (compare with almost 1.0 M in Figure 1 , when all three enzymes are present). Any further thrombin generation is prevented due to the inhibition of factor Xa. When the concentration of exogenous factor Xa is decreased by one order of magnitude (to 9.4 pM), thrombin generation is almost completely abolished (--). These data suggest that the presence of factor Xa in blood at the concentration reported for the factor X activation peptide would cause clot formation in less than 1 min. On the other hand, at concentrations 9.4 pM, factor Xa alone would not be able to trigger thrombin generation above the coagulation threshold. It will be inhibited by TFPI and AT-III before producing enough thrombin required for its own amplification. II. Empirical models. The data generated in computer simulations and presented in Figures 1-3 suggest that, in the absence of tissue factor, the major trigger of thrombin generation in vivo should be factor IXa if present at concentrations related to the reported amount of factor IX activation peptide. Thrombin and factor Xa play an accessory role to the factor IXa induced thrombin generation. To test the validity of predictions obtained in computer simulations, two empirical models of blood coagulation were used: synthetic plasma and whole blood.
B. The influence of factor
In the synthetic plasma reconstituted with washed platelets at mean physiologic concentration 
DISCUSSION
Activation peptides of the vitamin K-dependent proteins are reported to be present in the blood of normal individuals (6, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) ; altered levels of these peptides correlate with various coagulation disorders (11) (12) (13) (14) (15) (16) (17) (18) (19) and risk factors related to these disorders (20) (21) (22) (23) (24) (25) (26) .
One hypothesis ( Several observations related to the mechanism of thrombin generation can be made based upon the data of the current study. Only factor IXa at the picomolar concentrations relevant to the reported concentration of factor IX activation peptide is able to trigger thrombin generation similar to that observed with the mixture of all three enzymes used as an initiator. Factor IXa at those concentrations generates enough factor Xa for the production of initial amounts of thrombin. The latter amplifies its own generation through the activation of factor V and factor VIII. Although factor Xa is efficiently inhibited by TFPI (50), a relatively poor inhibition of factor IXa by antithrombin-III (51) allows generation of factor Xa for a prolonged period of time keeping prothrombin activation alive. A decrease in factor IXa concentration prolongs the initiation phase of thrombin generation due to the slower factor X activation.
In the reaction system lacking tissue factor, i.e. an essential component of the physiologic activator of factor IX and factor X, factor Xa can trigger thrombin generation above the coagulation threshold (>10 nM) (33, 43) only when present at the highest concentration tested (94 pM). The maximum concentration of thrombin produced, however, is much lower than that observed in the presence of factor IXa alone. At a lower factor Xa concentration (9.4 pM), factor Xa is inhibited by TFPI and AT-III (51) prior to the generation of detectable amounts of thrombin.
In the numerical simulations, thrombin even at the highest concentration used (1 nM) does not trigger its own generation. However, whole blood initiated with 1 nM thrombin in the absence of tissue factor clotted in 119 s suggesting relatively rapid thrombin generation. This discrepancy between the two models occurs due to the absence of factor XI in the numerical simulations, and, as a consequence, the absence of an efficient pathway of factor IX and factor X activation because the only enzymes present in the system are thrombin and 0.1 nM factor VIIa. The numerical model is an evolving entity, and new proteins, reactions and their kinetic constants have been and will be added to this model.
The data obtained when two enzymes are used simultaneously as a trigger of thrombin generation show that only the concentration of factor IXa has a pronounced effect on the process.
Although factor Xa and thrombin initiate prothrombin activation in the absence of factor IXa, the maximum concentration of thrombin produced is relatively low, resembling that observed in hemophilia (29, 34) . The absence of factor Xa when thrombin and factor IXa are present, has almost no effect on prothrombin activation, presumably due to the rapid activation of factor V and factor VIII by thrombin (30, (31) (32) (33) and, as a result, robust factor Xa generation by the factor IXa/factor VIIIa complex. The absence of initiating thrombin when factor IXa and factor Xa are present as initiators of thrombin generation has almost no effect on rates of prothrombin activation and maximum levels of thrombin achieved. The initiation phase, however, is slightly prolonged in the absence of thrombin. This delay in the onset of the propagation phase is related to the time required to generate initial amounts of thrombin by factor Xa. When produced, thrombin amplifies its own generation by activating factor V and factor VIII.
In conclusion, the data of this study suggest that concentrations of coagulation enzymes circulating in vivo are significantly lower than can be predicted from the reported concentrations of their activation peptides and rates of their inhibition by AT-III and TFPI. These peptides thus probably represent a "historical record" rather than an "idling motor". Our results suggest that in prothrombotic disease states, which are characterized by increased levels of activation peptides, exceptional attention has to be paid to the concentration of the factor IX activation peptide due to the high efficiency of factor IXa in initiation of thrombin generation. 
